Immunological function of the endothelial cell within the setting of organ transplantation

Immunology Letters

Volumn 139, Issue 1-2, 2011, Pages 1-6

  Taflin, Cécile ^a   Charron, Dominique ^a,b   Glotz, Denis ^a,b,c   Mooney, Nuala ^a,b  

^a INSERM   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c SAINT LOUIS HOSPITAL   (France)

Author keywords

Immune regulation; Inflammation; Organ transplantation

Indexed keywords

BETA INTERFERON; CD31 ANTIGEN; GAMMA INTERFERON; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1ALPHA; MAJOR HISTOCOMPATIBILITY ANTIGEN; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

ACUTE GRAFT REJECTION; ANTIBODY DETECTION; ANTIGEN PRESENTING CELL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL EXPANSION; CELL FUNCTION; CELL PROLIFERATION; CELL SURVIVAL; CELLULAR IMMUNITY; CYTOKINE PRODUCTION; ENDOTHELIUM; ENDOTHELIUM CELL; HUMAN; IMMUNE RESPONSE; NATURAL KILLER CELL; NONHUMAN; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; VASCULAR ENDOTHELIUM;

ANIMALS; ANTIGEN-PRESENTING CELLS; ENDOTHELIAL CELLS; HUMANS; ISOANTIBODIES; ORGAN TRANSPLANTATION; TRANSPLANTATION IMMUNOLOGY; TRANSPLANTATION, HOMOLOGOUS;

EID: 79960699389     PISSN: 01652478     EISSN: 18790542     Source Type: Journal    
DOI: 10.1016/j.imlet.2011.04.014     Document Type: Review

References (91)

1. Epperson D.E., Pober J.S. Antigen-presenting function of human endothelial cells. Direct activation of resting CD8 T cells. J Immunol 1994, 153:5402-5412.
2. Marelli-Berg F.M., Hargreaves R.E., Carmichael P., Dorling A., Lombardi G., Lechler R.I. Major histocompatibility complex class II-expressing endothelial cells induce allospecific nonresponsiveness in naive T cells. J Exp Med 1996, 183:1603-1612.
3. LaGier A.J., Pober J.S. Immune accessory functions of human endothelial cells are modulated by overexpression of B7-H1 (PDL1). Hum Immunol 2006, 67:568-578.
4. + T cell activation and cytolysis. Eur J Immunol 2003, 33:3117-3126.
5. + T lymphocytes in a B7-dependent fashion. J Immunol 2002, 169:6154-6161.
6. + T cells and trigger acute rejection: an alternative mechanism of allorecognition. Nat Med 2002, 8:233-239.
7. + lymphocytes. Transplantation 1993, 56:656-661.
8. + direct allorecognition in graft rejection. J Immunol 2004, 173:3027-3034.
9. + regulatory T cells. J Immunol 2005, 175:6265-6270.
10. Hughes C.C., Savage C.O., Pober J.S. Endothelial cells augment T cell interleukin 2 production by a contact-dependent mechanism involving CD2/LFA-3 interaction. J Exp Med 1990, 171:1453-1467.
11. Trpkov K., Campbell P., Pazderka F., Cockfield S., Solez K., Halloran P.F. Pathologic features of acute renal allograft rejection associated with donor-specific antibody. Analysis using the Banff grading schema. Transplantation 1996, 61:1586-1592.
12. Halloran P.F., Wadgymar A., Ritchie S., Falk J., Solez K., Srinivasa N.S. The significance of the anti-class I antibody response. I. Clinical and pathologic features of anti-class I-mediated rejection. Transplantation 1990, 49:85-91.
13. Halloran P.F., Schlaut J., Solez K., Srinivasa N.S. The significance of the anti-class I response. II. Clinical and pathologic features of renal transplants with anti-class I-like antibody. Transplantation 1992, 53:550-555.
14. Racusen L.C., Colvin R.B., Solez K., Mihatsch M.J., Halloran P.F., Campbell P.M., et al. Antibody-mediated rejection criteria-an addition to the Banff 97 classification of renal allograft rejection. Am J Transplant 2003, 3:708-714.
15. Le Bas-Bernardet S., Hourmant M., Valentin N., Paitier C., Giral-Classe M., Curry S., et al. Identification of the antibodies involved in B-cell crossmatch positivity in renal transplantation. Transplantation 2003, 75:477-482.
16. Susal C., Opelz G. Kidney graft failure and presensitization against HLA class I and class II antigens. Transplantation 2002, 73:1269-1273.
17. Loupy A., Suberbielle-Boissel C., Hill G.S., Lefaucheur C., Anglicheau D., Zuber J., et al. Outcome of subclinical antibody-mediated rejection in kidney transplant recipients with preformed donor-specific antibodies. Am J Transplant 2009, 9:2561-2570.
18. Gloor J., Cosio F., Lager D.J., Stegall M.D. The spectrum of antibody-mediated renal allograft injury: implications for treatment. Am J Transplant 2008, 8:1367-1373.
19. Campos E.F., Tedesco-Silva H., Machado P.G., Franco M., Medina-Pestana J.O., Gerbase-DeLima M. Post-transplant anti-HLA class II antibodies as risk factor for late kidney allograft failure. Am J Transplant 2006, 6:2316-2320.
20. Langan L.L., Park L.P., Hughes T.L., Irish A., Luxton G., Witt C.S., et al. Post-transplant HLA class II antibodies and high soluble CD30 levels are independently associated with poor kidney graft survival. Am J Transplant 2007, 7:847-856.
21. Issa N., Cosio F.G., Gloor J.M., Sethi S., Dean P.G., Moore S.B., et al. Transplant glomerulopathy: risk and prognosis related to anti-human leukocyte antigen class II antibody levels. Transplantation 2008, 86:681-685.
22. Loupy A., Hill G.S., Suberbielle C., Charron D., Anglicheau D., Zuber J., et al. Significance of C4d Banff scores in early protocol biopsies of kidney transplant recipients with preformed donor-specific antibodies (DSA). Am J Transplant 2011, 11:56-65.
23. Hood B., Olander R., Nagy Z., Bergentz S.E. Glomerulopathy in the transplanted kidney. Scand J Urol Nephrol 1970, 4:135-142.
24. Cosio F.G., Gloor J.M., Sethi S., Stegall M.D. Transplant glomerulopathy. Am J Transplant 2008, 8:492-496.
25. Sumitran-Holgersson S. Relevance of MICA and other non-HLA antibodies in clinical transplantation. Curr Opin Immunol 2008, 20:607-613.
26. Kayler L.K., Farber J.L., Colombe B., LaCava D., Friedewald J.J., Ratner L.E. Characterization of rejection episodes in patients following positive crossmatch and ABO-incompatible live donor renal transplantation. Transpl Int 2006, 19:128-139.
27. Jurcevic S., Ainsworth M.E., Pomerance A., Smith J.D., Robinson D.R., Dunn M.J., et al. Antivimentin antibodies are an independent predictor of transplant-associated coronary artery disease after cardiac transplantation. Transplantation 2001, 71:886-892.
28. Dragun D., Muller D.N., Brasen J.H., Fritsche L., Nieminen-Kelha M., Dechend R., et al. Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection. N Engl J Med 2005, 352:558-569.
29. Morgun A., Shulzhenko N., Unterkircher C.S., Diniz R.V., Pereira A.B., Silva M.S., et al. Pre- and post-transplant anti-myosin and anti-heat shock protein antibodies and cardiac transplant outcome. J Heart Lung Transplant 2004, 23:204-209.
30. Wagenknecht D.R., Becker D.G., LeFor W.M., McIntyre J.A. Antiphospholipid antibodies are a risk factor for early renal allograft failure. Transplantation 1999, 68:241-246.
31. Millington T.M., Madsen J.C. Innate immunity and cardiac allograft rejection. Kidney Int 2010, 78:S18-21.
32. Feucht H.E., Schneeberger H., Hillebrand G., Burkhardt K., Weiss M., Riethmuller G., et al. Capillary deposition of C4d complement fragment and early renal graft loss. Kidney Int 1993, 43:1333-1338.
33. Cascalho M., Platt J.L. Basic mechanisms of humoral rejection. Pediatr Transplant 2005, 9:9-16.
34. Racusen L.C., Halloran P.F., Solez K. Banff 2003 meeting report: new diagnostic insights and standards. Am J Transplant 2004, 4:1562-1566.
35. Uehara S., Chase C.M., Kitchens W.H., Rose H.S., Colvin R.B., Russell P.S., et al. NK cells can trigger allograft vasculopathy: the role of hybrid resistance in solid organ allografts. J Immunol 2005, 175:3424-3430.
36. Bender J.R., Pardi R., Engleman E. T-cell receptor-negative natural killer cells display antigen-specific cytotoxicity for microvascular endothelial cells. Proc Natl Acad Sci USA 1990, 87:6949-6953.
37. Candinas D., Belliveau S., Koyamada N., Miyatake T., Hechenleitner P., Mark W., et al. T cell independence of macrophage and natural killer cell infiltration, cytokine production, and endothelial activation during delayed xenograft rejection. Transplantation 1996, 62:1920-1927.
38. Gloor J.M., Sethi S., Stegall M.D., Park W.D., Moore S.B., DeGoey S., et al. Transplant glomerulopathy: subclinical incidence and association with alloantibody. Am J Transplant 2007, 7:2124-2132.
39. Sis B., Campbell P.M., Mueller T., Hunter C., Cockfield S.M., Cruz J., et al. Transplant glomerulopathy, late antibody-mediated rejection and the ABCD tetrad in kidney allograft biopsies for cause. Am J Transplant 2007, 7:1743-1752.
40. Li F., Atz M.E., Reed E.F. Human leukocyte antigen antibodies in chronic transplant vasculopathy-mechanisms and pathways. Curr Opin Immunol 2009, 21:557-562.
41. Jin Y.P., Singh R.P., Du Z.Y., Rajasekaran A.K., Rozengurt E., Reed E.F. Ligation of HLA class I molecules on endothelial cells induces phosphorylation of Src, paxillin, and focal adhesion kinase in an actin-dependent manner. J Immunol 2002, 168:5415-5423.
42. Jindra P.T., Jin Y.P., Rozengurt E., Reed E.F. HLA class I antibody-mediated endothelial cell proliferation via the mTOR pathway. J Immunol 2008, 180:2357-2366.
43. Harris P.E., Bian H., Reed E.F. Induction of high affinity fibroblast growth factor receptor expression and proliferation in human endothelial cells by anti-HLA antibodies: a possible mechanism for transplant atherosclerosis. J Immunol 1997, 159:5697-5704.
44. Yamakuchi M., Kirkiles-Smith N.C., Ferlito M., Cameron S.J., Bao C., Fox-Talbot K., et al. Antibody to human leukocyte antigen triggers endothelial exocytosis. Proc Natl Acad Sci USA 2007, 104:1301-1306.
45. Lepin E.J., Zhang Q., Zhang X., Jindra P.T., Hong L.S., Ayele P., et al. Phosphorylated S6 ribosomal protein: a novel biomarker of antibody-mediated rejection in heart allografts. Am J Transplant 2006, 6:1560-1571.
46. Le Bas-Bernardet S., Coupel S., Chauveau A., Soulillou J.P., Charreau B. Vascular endothelial cells evade apoptosis triggered by human leukocyte antigen-DR ligation mediated by allospecific antibodies. Transplantation 2004, 78:1729-1739.
47. Terasaki P.I., Ozawa M. Predicting kidney graft failure by HLA antibodies: a prospective trial. Am J Transplant 2004, 4:438-443.
48. Sis B., Jhangri G.S., Bunnag S., Allanach K., Kaplan B., Halloran P.F. Endothelial gene expression in kidney transplants with alloantibody indicates antibody-mediated damage despite lack of C4d staining. Am J Transplant 2009, 9:2312-2323.
49. Alexandre G.P., De Bruyere M., Squifflet J.P., Moriau M., Latinne D., Pirson Y. Human ABO-incompatible living donor renal homografts. Neth J Med 1985, 28:231-234.
50. Park W.D., Grande J.P., Ninova D., Nath K.A., Platt J.L., Gloor J.M., et al. Accommodation in ABO-incompatible kidney allografts, a novel mechanism of self-protection against antibody-mediated injury. Am J Transplant 2003, 3:952-960.
51. Platt J.L., Vercellotti G.M., Dalmasso A.P., Matas A.J., Bolman R.M., Najarian J.S., et al. Transplantation of discordant xenografts: a review of progress. Immunol Today 1990, 11:456-457. [450-6; discussion].
52. Nath K.A., Balla G., Vercellotti G.M., Balla J., Jacob H.S., Levitt M.D., et al. Induction of heme oxygenase is a rapid, protective response in rhabdomyolysis in the rat. J Clin Invest 1992, 90:267-270.
53. Bach F.H., Ferran C., Hechenleitner P., Mark W., Koyamada N., Miyatake T., et al. Accommodation of vascularized xenografts: expression of " protective genes" by donor endothelial cells in a host Th2 cytokine environment. Nat Med 1997, 3:196-204.
54. Mizel S.B., Kilian P.L., Lewis J.C., Paganelli K.A., Chizzonite R.A. The interleukin 1 receptor. Dynamics of interleukin 1 binding and internalization in T cells and fibroblasts. J Immunol 1987, 138:2906-2912.
55. Read M.A., Whitley M.Z., Williams A.J., Collins T. NF-kappa B and I kappa B alpha: an inducible regulatory system in endothelial activation. J Exp Med 1994, 179:503-512.
56. Griesemer A.D., Okumi M., Shimizu A., Moran S., Ishikawa Y., Iorio J., et al. Upregulation of CD59: potential mechanism of accommodation in a large animal model. Transplantation 2009, 87:1308-1317.
57. Uehara S., Chase C.M., Cornell L.D., Madsen J.C., Russell P.S., Colvin R.B. Chronic cardiac transplant arteriopathy in mice: relationship of alloantibody, C4d deposition and neointimal fibrosis. Am J Transplant 2007, 7:57-65.
58. Smith R.N., Kawai T., Boskovic S., Nadazdin O., Sachs D.H., Cosimi A.B., et al. Four stages and lack of stable accommodation in chronic alloantibody-mediated renal allograft rejection in Cynomolgus monkeys. Am J Transplant 2008, 8:1662-1672.
59. Farrelly N., Lee Y.J., Oliver J., Dive C., Streuli C.H. Extracellular matrix regulates apoptosis in mammary epithelium through a control on insulin signaling. J Cell Biol 1999, 144:1337-1348.
60. Newman P.J., Newman D.K. Signal transduction pathways mediated by PECAM-1: new roles for an old molecule in platelet and vascular cell biology. Arterioscler Thromb Vasc Biol 2003, 23:953-964.
61. Bennett V., Baines A.J. Spectrin and ankyrin-based pathways: metazoan inventions for integrating cells into tissues. Physiol Rev 2001, 81:1353-1392.
62. Al-Lamki R.S., Bradley J.R., Pober J.S. Endothelial cells in allograft rejection. Transplantation 2008, 86:1340-1348.
63. Chalasani G., Dai Z., Konieczny B.T., Baddoura F.K., Lakkis F.G. Recall and propagation of allospecific memory T cells independent of secondary lymphoid organs. Proc Natl Acad Sci USA 2002, 99:6175-6180.
64. Brewer Y., Palmer A., Taube D., Welsh K., Bewick M., Bindon C., et al. Effect of graft perfusion with two CD45 monoclonal antibodies on incidence of kidney allograft rejection. Lancet 1989, 2:935-937.
65. Shiao S.L., McNiff J.M., Pober J.S. Memory T cells and their costimulators in human allograft injury. J Immunol 2005, 175:4886-4896.
66. + T cells directly recognize allogeneic endothelial cells in vitro and in vivo. J Immunol 2007, 179:4397-4404.
67. Biedermann B.C., Pober J.S. Human endothelial cells induce and regulate cytolytic T cell differentiation. J Immunol 1998, 161:4679-4687.
68. Waaga A.M., Gasser M., Kist-van Holthe J.E., Najafian N., Muller A., Vella J.P., et al. Regulatory functions of self-restricted MHC class II allopeptide-specific Th2 clones in vivo. J Clin Invest 2001, 107:909-916.
69. Fanslow W.C., Clifford K.N., Park L.S., Rubin A.S., Voice R.F., Beckmann M.P., et al. Regulation of alloreactivity in vivo by IL-4 and the soluble IL-4 receptor. J Immunol 1991, 147:535-540.
70. Nickerson P., Zheng X.X., Steiger J., Steele A.W., Steurer W., Roy-Chaudhury P., et al. Prolonged islet allograft acceptance in the absence of interleukin 4 expression. Transpl Immunol 1996, 4:81-85.
71. Burlingham W.J., Love R.B., Jankowska-Gan E., Haynes L.D., Xu Q., Bobadilla J.L., et al. IL-17-dependent cellular immunity to collagen type V predisposes to obliterative bronchiolitis in human lung transplants. J Clin Invest 2007, 117:3498-3506.
72. + Th17 cells in mediating cardiac allograft rejection and vasculopathy. J Exp Med 2008, 205:3133-3144.
73. Battaglia M. Potential T regulatory cell therapy in transplantation: how far have we come and how far can we go?. Transpl Int 2010, 23:761-770.
74. + regulatory T cells suppress early stages of granuloma formation but have little impact on sarcoidosis lesions. Am J Pathol 2009, 174:497-508.
75. + T cells expressing the FoxP3 transcription factor. Immunity 2009, 30:899-911.
76. + regulatory T cells prevent graft rejection: CTLA-4- and IL-10-dependent immunoregulation of alloresponses. J Immunol 2002, 168:1080-1086.
77. + immune regulatory cells are required for induction of tolerance to alloantigen via costimulatory blockade. J Exp Med 2001, 193:1311-1318.
78. Wood K.J., Sakaguchi S., Regulatory T cells in transplantation tolerance. Nat Rev Immunol 2003, 3:199-210.
79. + regulatory T cell recruitment in human renal allograft infiltrates. J Immunol 2007, 179:4901-4909.
80. Kreisel D., Richardson S.B., Li W., Lin X., Kornfeld C.G., Sugimoto S., et al. Cutting edge: MHC class II expression by pulmonary nonhematopoietic cells plays a critical role in controlling local inflammatory responses. J Immunol 2010, 185:3809-3813.
81. Taflin C., Favier B., Baudhuin J., Savenay A., Hemon P., Bensussan A., et al. Human endothelial cells generate Th17 and regulatory T cells under inflammatory conditions. Proc Natl Acad Sci USA 2011, 108:2891-2896.
82. Muczynski K.A., Ekle D.M., Coder D.M., Anderson S.K. Normal human kidney HLA-DR-expressing renal microvascular endothelial cells: characterization, isolation, and regulation of MHC class II expression. J Am Soc Nephrol 2003, 14:1336-1348.
83. Hancock W.W., Kraft N., Atkins R.C. The immunohistochemical demonstration of major histocompatibility antigens in the human kidney using monoclonal antibodies. Pathology 1982, 14:409-414.
84. Kluger M.S., Johnson D.R., Pober J.S. Mechanism of sustained E-selectin expression in cultured human dermal microvascular endothelial cells. J Immunol 1997, 158:887-896.
85. Swerlick R.A., Lee K.H., Li L.J., Sepp N.T., Caughman S.W., Lawley T.J. Regulation of vascular cell adhesion molecule 1 on human dermal microvascular endothelial cells. J Immunol 1992, 149:698-705.
86. Swerlick R.A., Lee K.H., Wick T.M., Lawley T.J. Human dermal microvascular endothelial but not human umbilical vein endothelial cells express CD36 in vivo and in vitro. J Immunol 1992, 148:78-83.
87. Beck G., Ludwig F., Schulte J., van Ackern K., van der Woude F.J., Yard B.A. Fractalkine is not a major chemoattractant for the migration of neutrophils across microvascular endothelium. Scand J Immunol 2003, 58:180-187.
88. Manes T.D., Pober J.S. Antigen presentation by human microvascular endothelial cells triggers ICAM-1-dependent transendothelial protrusion by, and fractalkine-dependent transendothelial migration of, effector memory CD4+ T cells. J Immunol 2008, 180:8386-8392.
89. Carman C.V., Sage P.T., Sciuto T.E., de la Fuente M.A., Geha R.S., Ochs H.D., et al. Transcellular diapedesis is initiated by invasive podosomes. Immunity 2007, 26:784-797.
90. Kubota Y., Kleinman H.K., Martin G.R., Lawley T.J. Role of laminin and basement membrane in the morphological differentiation of human endothelial cells into capillary-like structures. J Cell Biol 1988, 107:1589-1598.
91. Charo I.F., Shak S., Karasek M.A., Davison P.M., Goldstein I.M. Prostaglandin I2 is not a major metabolite of arachidonic acid in cultured endothelial cells from human foreskin microvessels. J Clin Invest 1984, 74:914-919.